FDA allows Sentrian to market RPI mobile-health system
Sentrian said on Thursday that the Food and Drug Administration (FDA) has decided the company's Remote Patient Intelligence (RPI) mobile-health system meets the definition of a "medical device," on which the FDA intends to exercise "enforcement discretion." Read More »
Alerts Sign-up